Stepan Reports Second Quarter 2026 Results
Stepan (NYSE: SCL) reported Q2 2026 net income of $22.9M, up 102% year over year, and adjusted net income of $27.1M, up 126%. Adjusted EBITDA rose 45% to $74.4M. Net sales increased 15% to $684.1M, with organic volume up 6%. Free cash flow was -$15.0M due to working capital. The company plans to cut about 100 salaried roles under Project Catalyst and expects full-year restructuring charges of $75.0M-$80.0M.
How this was made
The 30-second read
Why it matters
The release combines strong adjusted profitability and organic volume growth with explicit restructuring plans and a near-term cash-flow drag from working capital, shaping both earnings and cash-flow expectations for 2026.
Market read
Traders can reassess near-term sentiment on adjusted earnings strength while monitoring the disclosed H2 restructuring ramp and the stated cash impact range for 2026.
What to watch
The restructuring expense is expected to be recognized mainly in H2 2026, which could pressure future reported earnings and keep investors focused on cash impact rather than adjusted metrics.
Background
Stepan is executing Project Catalyst, an efficiency initiative that includes asset optimization and organizational effectiveness actions.
Ticker impact
Stepan reported Q2 2026 results with adjusted EBITDA up 45% YoY and disclosed a salaried workforce reduction tied to Project Catalyst.
Near-term bias likely positive on adjusted earnings strength, but investors may focus on restructuring charges and the path back to positive free cash flow.
The article provides multiple concrete datapoints: adjusted EBITDA and organic volume growth, plus explicit restructuring charge range ($75.0 to $80.0 million) and cash impact ($14.0 to $18.0 million), which can drive valuation and forward cash-flow expectations.
Market effects
Read-through for specialty chemicals demand and pricing power via Surfactant and Polymer volume growth and margin recovery, plus evidence of cost actions (Project Catalyst).
Mentions broad-based organic volume growth across regions and end markets, with some Polymer weakness in Europe and Asia offset by North America strength.
Highlights geopolitical-driven customer pre-buys and ongoing supply-chain disruptions, which can affect near-term order patterns across global chemical supply chains.
Counterpoint
Reported free cash flow was negative ($15.0 million) and restructuring charges are still ramping, so equity upside may be limited until cash conversion improves.
Key entities
- companyStepan Company
Reported Q2 2026 results, including adjusted EBITDA growth, organic volume gains, and a plan to cut about 100 salaried roles under Project Catalyst.
